HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tam, S. K. Articles by Nadal-Ginard, B. Search for Related Content PubMed PubMed Citation Articles by Tam, S. K. Articles by Nadal-Ginard, B.

The Journal of Thoracic and Cardiovascular Surgery, Vol 109, Issue 5 918-923, Copyright © 1995 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

NOTE: The fulltext of this article is not available online.

Molecular cardiomyoplasty: potential cardiac gene therapy for chronic heart failure

S. K. Tam, W. Gu and B. Nadal-Ginard
Cardiac Surgical Unit, Massachusetts General Hospital, Boston, USA.

In this study, we evaluated the feasibility of converting cardiac fibroblasts into skeletal muscle cells by forced expression of the MyoD gene, one of the basic helix-loop-helix myogenic factors. Primary cardiac fibroblasts, isolated from newborn rats, were infected with retrovirus-carrying sense or antisense MyoD gene. Ten days after infection, expression of MyoD protein was demonstrated in 95% of cells infected with sense MyoD virus by intense nuclear immunostaining with a MyoD polyclonal antibody. In contrast, none of the cells infected with antisense MyoD virus showed staining. On withdrawal of serum, 95% of MyoD positive cells became elongated and, in the presence of appropriate cell density, fused to form multinucleated myotubes, morphologically similar to striated muscle cell. Expression of downstream myogenic differentiation markers, myosin heavy chain and myocyte-specific enhancer factor 2, in 95% of these myotubes were detected by intense cytoplasmic and nuclear immunostaining, respectively, with specific antibodies. In contrast, no detectable staining was noted in MyoD negative cells. Spontaneous contractile movements were noted in a few clusters of myotubes. In summary, cardiac fibroblasts were able to be converted into bonafide potentially functional skeletal myocytes as shown by definitive morphologic and biochemical changes. Further studies with in vivo models are needed to explore this unique molecular strategy to treat patients with chronic heart failure.

This article has been cited by other articles:

				P. Menasche Skeletal muscle satellite cell transplantation Cardiovasc Res, May 1, 2003; 58(2): 351 - 357. [Abstract] [Full Text] [PDF]

				P Menasche and M Desnos Cardiac reparation: fixing the heart with cells, new vessels and genes Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D73 - D81. [Abstract] [PDF]

				P. A. Doevendans, P. Ruiz-Lozano, and M. van Bilsen Hunting down nucleic acid binding factors in the cardiovascular system Cardiovasc Res, May 1, 1998; 38(2): 301 - 315. [Abstract] [Full Text] [PDF]

				J. Leor, H. Prentice, V. Sartorelli, M. J Quinones, M. Patterson, L. K Kedes, and R. A Kloner Gene transfer and cell transplant: an experimental approach to repair a 'broken heart' Cardiovasc Res, September 1, 1997; 35(3): 431 - 441. [Full Text] [PDF]

				I. Y. Christlieb, R. C.-J. Chiu, A. Zibaitis, and R. L. Kao Cellular Cardiomyoplasty Ann. Thorac. Surg., February 1, 1996; 61 (2): 772 - 773. [Full Text]